
Protagonist Therapeutics Inc
NASDAQ:PTGX

Intrinsic Value
The intrinsic value of one
PTGX
stock under the Base Case scenario is
15
USD.
Compared to the current market price of 45.66 USD,
Protagonist Therapeutics Inc
is
Overvalued by 67%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Protagonist Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Protagonist Therapeutics Inc
Balance Sheet Decomposition
Protagonist Therapeutics Inc
Current Assets | 591.6m |
Cash & Short-Term Investments | 418.9m |
Receivables | 168.5m |
Other Current Assets | 4.2m |
Non-Current Assets | 153.1m |
Long-Term Investments | 140.3m |
PP&E | 12.6m |
Other Non-Current Assets | 225k |
Free Cash Flow Analysis
Protagonist Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Protagonist Therapeutics Inc
Revenue
|
434.4m
USD
|
Operating Expenses
|
-181.6m
USD
|
Operating Income
|
252.8m
USD
|
Other Expenses
|
22.3m
USD
|
Net Income
|
275.2m
USD
|
PTGX Profitability Score
Profitability Due Diligence
Protagonist Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Score
Protagonist Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
PTGX Solvency Score
Solvency Due Diligence
Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Protagonist Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PTGX Price Targets Summary
Protagonist Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
PTGX
is 70.83 USD
with a low forecast of 45.45 USD and a high forecast of 86.1 USD.
Dividends
Current shareholder yield for PTGX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PTGX
stock under the Base Case scenario is
15
USD.
Compared to the current market price of 45.66 USD,
Protagonist Therapeutics Inc
is
Overvalued by 67%.